RhumbLine Advisers’s Endocyte, Inc. Common Stock ECYT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2018
Q4 | – | Sell |
-59,497
| Closed | -$1.06M | – | 2987 |
|
|
2018
Q3 | $1.06M | Sell |
59,497
-3,368
| -5% | -$59.8K | ﹤0.01% | 1984 |
|
|
2018
Q2 | $868K | Buy |
+62,865
| New | +$868K | ﹤0.01% | 2071 |
|
|
2017
Q2 | – | Sell |
-43,259
| Closed | -$111K | – | 2987 |
|
|
2017
Q1 | $111K | Buy |
43,259
+553
| +1% | +$1.42K | ﹤0.01% | 2767 |
|
|
2016
Q4 | $109K | Sell |
42,706
-1,731
| -4% | -$4.42K | ﹤0.01% | 2786 |
|
|
2016
Q3 | $137K | Buy |
44,437
+400
| +0.9% | +$1.23K | ﹤0.01% | 2764 |
|
|
2016
Q2 | $141K | Sell |
44,037
-14,738
| -25% | -$47.2K | ﹤0.01% | 2849 |
|
|
2016
Q1 | $182K | Buy |
58,775
+5,310
| +10% | +$16.4K | ﹤0.01% | 2762 |
|
|
2015
Q4 | $214K | Buy |
53,465
+4,215
| +9% | +$16.9K | ﹤0.01% | 2761 |
|
|
2015
Q3 | $226K | Buy |
49,250
+2,715
| +6% | +$12.5K | ﹤0.01% | 2718 |
|
|
2015
Q2 | $242K | Buy |
46,535
+9,710
| +26% | +$50.5K | ﹤0.01% | 2781 |
|
|
2015
Q1 | $231K | Buy |
36,825
+5,900
| +19% | +$37K | ﹤0.01% | 2759 |
|
|
2014
Q4 | $195K | Buy |
30,925
+900
| +3% | +$5.68K | ﹤0.01% | 2827 |
|
|
2014
Q3 | $183K | Sell |
30,025
-1,200
| -4% | -$7.31K | ﹤0.01% | 2794 |
|
|
2014
Q2 | $206K | Buy |
31,225
+3,851
| +14% | +$25.4K | ﹤0.01% | 2817 |
|
|
2014
Q1 | $652K | Sell |
27,374
-1,490
| -5% | -$35.5K | ﹤0.01% | 2047 |
|
|
2013
Q4 | $309K | Hold |
28,864
| – | – | ﹤0.01% | 2569 |
|
|
2013
Q3 | $385K | Sell |
28,864
-267
| -0.9% | -$3.56K | ﹤0.01% | 2372 |
|
|
2013
Q2 | $382K | Buy |
+29,131
| New | +$382K | ﹤0.01% | 2473 |
|